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CHAPTER ONE
OVERVIEW AND HYPOTHESES

A major barrier to HIV eradication is the persistence of latent viral reservoirs that
exist despite antiretroviral therapy. Latent reservoirs are primarily made up of memory
CD4+ T cells, which become infected while activated and survive long enough to revert
to a quiescent state that is non-permissive for viral gene expression (Siliciano et al.,
2011). Current HIV research is focused on eliminating this pool of latently infected cells
by the “shock and kill” method, which involves purging the virus out of latency using a
variety of compounds that force viral gene expression (Jordan et al., 2003; Colin et al.,
2009). Cells producing virus will be targeted by host immune responses, while
antiretroviral drugs prevent new rounds of infection. However, this method has proven
difficult since these drugs are unable to reactivate each latent provirus, leading some to
suggest that HIV latency and reactivation is stochastic (Ho et al., 2013; Weinberger et al.,
2013).
Stress and alcohol consumption are prevalent among HIV-infected individuals,
having deleterious effects on the immune system (Glasser et al., 2005; Justice et al.,
2013). Glucocorticoids and ethanol mediate their effects by altering cell signaling
pathways, the activity of transcription factors (NF-kB, AP-1), and inducing epigenetic
modifications that alter the expression of immune response genes and consequently,
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immune cell function (Nelson et al., 2003; Webster et al., 2002; Krukowski et al., 2011;
Curtis et al., 2013; Arror et al., 2004; Thannickal et al., 2000). These glucocorticoid and
ethanol-induced modifications likely have profound effects on HIV latency since
transcription factor availability and epigenetic mechanisms play a role in the
establishment, maintenance, and reactivation of latently infected cells.
In order to develop effective therapeutics, a comprehensive understanding of
latency and factors driving the formation of the latent reservoir is needed. As stress and
alcohol are common comorbidities associated with HIV infection, the goal of this
research was to determine how stress and alcohol could affect HIV-latency. Specifically,
we hypothesized that the ability of latent proviruses to be reactivated by “shock and kill”
approaches would be altered by glucocorticoid and ethanol treatments, and prolonged
ethanol exposure would affect the size of the latent reservoir. To test our hypothesis, we
examined two aspects of latency. In aim 1 we assessed whether viral reactivation was
altered by dexamethasone and ethanol treatments. We then addressed how
dexamethasone and ethanol exposure could affect the establishment of latent reservoirs in
aim 2.

CHAPTER TWO
INTRODUCTION

Human immunodeficiency virus-1 (HIV-1) is the causative agent of Acquired
Immunodeficiency Syndrome (AIDS), which caused more than 1.5 million deaths
worldwide in 2013 alone (World Health Organization, 2014). According to the World
Health Orgnaization, an estimated 35 million people are currently living with HIV
(World Health Organization, 2014). Because this virus targets immune cells, namely
CD4+ T cells, the depletion of the cells overtime leads to immunosuppression and gives
rise to opportunistic infections, to which patients eventually succumb. The introduction
of highly active antiretroviral therapy (HAART) has significantly reduced the morbidity
and mortality rates, as it slows the loss of these immune cells and progression to AIDS
(Van Lint et al., 2013). Unfortunately, HAART is unable to completely eradicate HIV
infection, as any interruption in therapy results in a rapid viral rebound. This is because
infected patients harbor transcriptionally silent but replication-competent viral reservoirs
that exists even in the continued presence of antiretroviral drugs (Van Lint et al., 2013).

HIV INFECTION CYCLE
Inside each HIV viral particle are two identical positive sense RNAs associated
with multiple proteins. Group antigen (gag) proteins make up the structural elements of
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the virus and include the nucleoproteins that surround the RNA. A number of enzymes
are present in the core, including reverse transcriptase, ribonuclease H, protease, and
integrase. Surrounding the core is a lipid envelope comprised of glycoproteins gp120 and
gp41. These structural proteins, enzymes, and envelope glycoproteins are encoded in
three genes in the HIV genome, gag, pol, and env, respectively.
The HIV genome also includes accessory genes vif, vpu, vpr, and nef and
regulatory genes tat and rev. The proteins encoded by these genes carry out many
important functions for the HIV infection cycle. Briefly, Vif plays a role in viral
replication and promotes the degradation of APOBEC3G, a restriction factor that
hypermutates viral cDNA, preventing efficient infectivity (Trono, 1995; Rose et al.,
2004). Vpu stimulates virion release and CD4 degradation. Vpr aids in the infection of
non-dividing cells, such as terminally differentiated macrophages, and can induce cell
cycle arrest (Trono, 1995). Nef enhances HIV-1 infectivity and triggers CD4 downregulation (Trono, 1995). Rev regulates transport of nascent viral mRNAs into the
cytoplasm for translation (Uberla, 2010). Tat acts as a potent transcriptional activator.
Upon translation, Tat comes back into the nucleus, binds the trans-activating response
element (TAR), and recruits cellular transcription machinery to initiate effective
transcription of the entire viral genome from the 5’LTR (Romani et al., 2010).
Viral entry occurs at mucosal surfaces, primarily through sexual contact. Gp120
binds CD4 receptors, causing a conformational change that allows binding to a
coreceptor, either CCR5 or CXCR4 (Wilen et al., 2012; Doms et al., 2000). Following
coreceptor binding, gp41 becomes exposed and penetrates the target cell membrane,
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allowing the two membranes to come together and ultimately fuse (Doms et al., 2000;
Engelman et al., 2012).
After HIV fuses to the target cell, the viral core gets released into the host cell
cytoplasm and reverse transcription is initiated. tRNAs hybridized to the viral RNAs
prime cDNA synthesis and reverse transcriptase converts the RNAs to double stranded
DNA (Hu et al., 2012). Ribonuclease H (RNase H) degrades RNA after it has served as a
template for reverse transcription (Hu et al., 2012). The karyophilic pre-integration
complex (PIC) enters the nucleus, and integrase embeds the provirus into the host cell
chromosome, preferentially in areas of active transcription near the nuclear periphery
(Craigie et al., 2012; Albanese et al., 2008). At this point, the virus can be transcribed.
RNA polymerase II and associated transcription factors bind the HIV-LTR and drive
transcription of gag, pol and env. Spliced mRNAs escape into the cytoplasm, and unspliced or incompletely spliced viral RNAs get exported from the nucleus with the help
of Rev (Sundquist et al., 2012).
The viral glycoproteins are synthesized from an env/vpu mRNA transcript that is
translated on the rough ER. The glycoprotein precursor (gp160) becomes glycosylated,
oligomerizes and traffics to the Golgi where it is further processed into gp120 and gp41
(Checkley et al. 2012). These glycoproteins traffic via the secretory pathway and are
deposited on the plasma membrane. Gag-pol mRNA translates into multiple gag proteins
and a gag-pol polyprotein generated by translational frameshifting (Sundquist et al.,
2012). This gag-pol polyprotein houses the viral protease, reverse transcriptase and
integrase.
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Translated products, including two copies of viral RNA, cellular tRNA, and the
viral structural and enzymatic proteins (gag proteins and gag-pol polyprotein) assemble at
the plasma membrane (Sundquist et al., 2012). The envelope is acquired from the host
cell membrane as the virus buds. Maturation is a largely extracellular event driven by the
viral protease. Immature virions that bud out from a host cell are not infectious. PR
cleaves specific sites within Gag, so that Gag constituent proteins can condense and
rearrange forming the conical core of a mature virus (Sundquist et al., 2012). Mature
viruses can go on to infect other cells, and the cycle continues.
HAART is comprised of a cocktail of drugs such as reverse transcription
inhibitors, protease inhibitors, fusion inhibitors and integration inhibitors, which are
designed to target different phases of the HIV life cycle (Engleman et al., 2012). The
concomitant administration of these drugs is intended to prevent the emergence of
antiretroviral-drug resistant viruses. While HAART has successfully slowed progression
to AIDS, there are many side-effects to long term antiretroviral (Van Lint et al., 2013).
Unfortunately, cessation of therapy is not an option, as any interruption in HAART is
followed by rapid viral rebound. This is due to the existence of latent reservoirs.

HIV LATENCY
Background
After entry and integration, some viruses get transcribed and enter the productive
infection cycle described above. Alternatively, some proviruses enter a latent state. The
latent reservoir is primarily comprised of memory CD4+ T cells (Siliciano et al., 2011;
Donahue et al., 2013). HIV has high tropism for activated CD4+ T cells. Once infected,
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many of these cells undergo cell death due to cytotoxic effects of the virus or recognition
by host immune responses. A subset of infected cells survive and enter a quiescent or
memory state, forming long-lived memory T cells (Siliciano et al. 2011). This latent
reservoir is intrinsically stable and the progressive loss of these cells is very slow
(Siliciano et al., 2011; Van Lint et al., 2013). It has been estimated that it would take over
70 years to eradicate this pool of latently infected cells from a patient on HAART
(Silicano et al., 2011). As a result, patients have to remain on antiretroviral drugs for the
remainder of their lives.
Latency is established reproducibly during HIV infection. The number of latently
infected cells in a HIV-infected individual is low, ranging between 1-10 million cells per
individual (Jordan et al., 2003). Current HIV research is focused on eliminating this pool
of latently infected cells, as they represent a major barrier to viral eradication. One
proposed eradication strategy involves purging the virus out of latency using a variety of
compounds that force viral gene expression. The idea here is that reactivated cells will
begin to produce virus and will be eliminated by host immune responses and/or HIVmediated cell death, while new rounds of infection will be prevented by antiretroviral
drugs (Jordan et al., 2003; Colin et al., 2009; Van Lint et al., 2013). The numerous
mechanisms maintaining the latent state (such as transcriptional interference, absence of
host transcription factors, numerous repressive epigenetic modifications, etc.) make
complete eradication by this ‘shock and kill’ approach unlikely (Siliciano et al., 2011;
Colin et al., 2009). In theory, a single latently infected cell can cause viral rebound,
meaning that complete eradication requires drugs that will induce viral expression in all
latently infected cells. The more realistic goal of viral purging would be to reduce the size
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of the latent reservoir to a level where the immune system can control the virus, at least
long enough to allow interruptions in antiretroviral treatments (Colin et al., 2009).

Mechanisms of latency and proviral reactivation
Chromatin remodeling mechanisms are a major determinant in transcription of the
HIV genome. Two nucleosomes, nuc-0 and nuc-1, are important regulators of HIV
transcription. They are positioned near the HIV-LTR and overlap with important
transcription factor binding sites (Siliciano et al., 2011). Remodeling of nuc-1, which is
positioned just downstream of the transcription start site, is associated with viral
reactivation (Shirakawa et al., 2013; Siliciano et al., 2011; Van Lint et al., 2013).
Importantly, treatment with HDAC inhibitors alone allows for this remolding of nuc-1
and subsequent viral reactivation (Shirakawa et al., 2013; Siliciano et al., 2011).
Histone deaceytlases (HDACs) repress transcription by deacetylating histone
proteins near the viral promoter. These HDACs get recruited to the HIV-LTR by various
transcription factors, such as Ying-Yang I (YY1), late SV40 factor (LSF), COUP-TF
interacting protein (CTIP2), c-promoter-binding factor-1 (CBF-1), thyroid hormone
receptor, NF-kB p50 homodimer, and c-myc and Sp1 (Shirakawa et al., 2013; Siliciano et
al., 2011). Histone deacetylase inhibitors activate transcription by inhibiting the activities
of HDACs. Inhibition of class I HDACs by HDAC inhibitors such as Trichostatin A
(TSA), Vorinostat (SAHA), Valproic acid (VPA) and a number of other drugs have been
studied in regards to HIV latency. SAHA and VPA had moderate success in some clinical
trials, but failed to induce viral reactivation in subsequent studies (Shirakawa et al., 2013;
Spina et al., 2013; Siliciano et al., 2011).
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DNA methylation of CpG islands that flank the transcription start site also
contribute the proviral latency. Consistent with this, chromatin associated with H3K9me2
and H3K27me3 histone modification marks found near the nuclear periphery in laminaassociated domains (LADs) (Kind et al., 2010). Genes in these LADs have very low
expression (Kind et al., 2010). The mechanism of methylation involves recruitment of the
methyl binding protein MBD2 and the nucleosome remodeling and histone deacetylation
(NuRD) complex (Shirakawa et al., 2013; Spina et al., 2013; Siliciano et al., 2011). AzaCdR, a DNA methylation inhibitor, acts synergistically with NF-kB activators to induce
viral reactivation (Blazkova et al., 2009; Siliciano et al., 2011).
A number of host transcription factors are essential for transcription from the
HIV-LTR. NFAT, NF-kB and AP-1 are sequestered in the cytoplasm of resting T cells,
thus coupling proviral transcription with T cell activation (Siliciano et al., 2011; Van Lint
et al., 2013; Coffin et al., 1997). Another transcription factor found to be important in
viral reactivation is Sp1. Sp1 remains inactive in quiescent cells, but upon entry into the
cell division cycle, it becomes activated and initiates proviral transcription (Bosque et al.,
2009). Many drugs used to purge latent reservoirs target these transcription factors to
initiate viral reactivation, such as TNFα and TPA, which activate NF-kB and PKC,
respectively.

Models of HIV latency
Latently infected cells in vivo are present in low numbers and are phenotypically
indistinguishable from uninfected cells, making studying HIV latency difficult (Spina et
al., 2013). A number of in vitro and ex vivo models of HIV latency have emerged in the
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past decade, that have been useful for studying how latency gets established, mechanisms
maintaining the latent state, and identifying latency reversing agents for viral
reactivation. The J-Lat cell model developed by Verdin and colleagues has been widely
used to study mechanisms of HIV latency and the efficacy of potential latency reversing
agents. J-Lat cells were derived by infecting Jurkat T cells with an HIV-based retroviral
vector containing wild-type tat and a GFP reporter (Jordan et al., 2003). Four days after
infection, GFP-negative cells were selected by FACS. To separate the latently infected
from the uninfected cells, cells were treated with TPA or TNFa to activate HIV
expression, and the GFP-positive cells were isolated by FACS. This population of cells
represents latently infected cells that only express viral proteins after activation (Jordan et
al., 2003). Individual cells were cloned and have been studied particularly for
mechanisms of viral reactivation, which can be easily monitored by flow cytometry.
While latently infected T cell lines have contributed substantially to the field,
there are disparities across model systems, as a single cell model is unable to fully
recapitulate the biological characteristics of latently infected cells in HIV-infected
patients (Spina et al., 2013). Primary cell models more accurately reflect the properties of
latently infected cells in vivo and are therefore important for studying HIV latency. The
Bosque and Planelles model involves the establishment of latently infected effector and
central memory T cells (Bosque et al., 2009). In this model, naïve CD4+ T cells isolated
from PBMCs are activated with anti-CD3 and anti-CD28 and primed toward
differentiation into Th1, Th2 and non-polarized subsets (Bosque et al, 2009).
Differentiated cells are infected, and latency is established by day 7 after infection
(Bosque et al., 2009). Another primary cell model developed by the Karn and colleagues
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obtained a population of latently infected CD4+ T cells by infecting activated CD4s with
a lentiviral vector expressing a GFP reporter, isolating the GFP-positive cells by FACS,
and cultivating infected cells on feeder cells to allow transcriptional silencing (Tyagi et
al., 2010). The result is a population of latently infected cells with a quiescent phenotype
that can be maintained in culture for months (Tyagi et al., 2010).

Stochasticity of latent proviruses
It has recently been proposed that the reactivation of HIV from latent reservoirs is
stochastic (Ho et al., 2013). The stochastic model suggests that viral entrance into latency
occurs by chance, and viral reactivation is therefore probabilistic. This idea comes from
multiple findings that not all latent viruses become reactivated upon cellular activation.
The Siliciano group analyzed various factors that could potentially explain why these
intact proviruses were not being expressed in activated cells, while identical proviruses
were reactivated (Weinberger et al., 2013). They found that while most non-induced
viruses were defective (mediated by APOBEC3G-induced hypermutation), some
proviruses remained silent despite cellular activation. These proviruses were not
integrated into heterochromatin, there was little CpG methylation at the viral promoter,
and transcriptional interference did not account for the proviral silencing. As a result of
these findings, they concluded that the reactivation of latent proviruses is stochastic, even
after maximum activation (Ho et al., 2013).

STRESS AND IMMUNE FUNCTION
Numerous studies demonstrate that stress influences immune function and can
contribute to disease progression (Capitanio et al., 1998; Glasser et al., 2005; Krukowski
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et al., 2011.). As stressors are perceived in the brain, the hypothalamic-pituitary-adrenal
(HPA) axis is stimulated, resulting in the release of adrenocorticotropic hormones by the
pituitary gland and the production of glucocorticoid hormones. Release of
glucocorticoids into the circulation can result in modulation of the immune system, as
glucocorticoid receptors (GR) are expressed by most immune cells (Glassar et al., 2005).
In these cells, the glucocorticoid hormones bind their cognate receptor, activating it.
Ligand-activated GR rapidly translocates into the nucleus where it dimerizes with another
activated GR. The homodimer binds glucocorticoid response elements (GREs) in the
promoter of GC-sensitive genes and activates transcription (Shacke et al., 2004). The
HIV promoter contains GRE-like sequences, so it is possible that glucocorticoid exposure
could have a positive effect on viral transcription (Coffin et al., 1997; Kino et al., 2000).
Additionally, the viral protein Vpr has been shown to enhance the effect of
glucocorticoids by interacting directly with the GR (Kino et al., 2000; Kino et al., 1999).
Glucocorticoids can also repress the expression of certain genes, particularly
those involved in immune responses (Nelson et al., 2003). In the nucleus, the GR can
form a heterodimer with transcription factors, such as NF-kB and AP-1, preventing
transactivation of their target genes (Webster et al., 2002). The transrepressive effects of
activated GR also occur in the cytoplasm, where the GR indirectly prevents the
translocation of transcription factors into the nucleus. For example, ligand-activated GR
induces synthesis of IkB, which sequesters NF-kB in the cytoplasm (Auphan et al.,
1995). Additionally, glucocorticoids can mediate their anti-inflammatory affects by
inhibiting signaling cascades (Nelson et al., 2003). A number of cytokines, such as IL-2,
elicit their effects via the Jak-STAT signaling pathway, and inhibition of this signaling
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cascade by glucocorticoid treatment has suppressive effects on immune cell function
(Bianchi et al., 2000). The primary way glucocorticoids dysregulate immune function is
by inducing epigenetic modifications that alter the activation status of immune response
genes. Specifically, glucocorticoids actively recruit histone deacetylase complexes and
inhibit histone acetyltransferase activity, resulting in histone deacetylation and reduced
gene expression. This has been shown in natural killer cells, where treatment with
dexamethasone, a synthetic glucocorticoid, results in decreased natural killer cell activity
(Krukowski et al., 2011).
Stress has previously been shown to accelerate HIV disease progression. One
study showed that socially stressed rhesus macaques infected with simian
immunodeficiency virus (SIV) had higher concentrations of viral RNA in the plasma and
died more quickly compared to infected rhesus macaques in stable social conditions
(Glasser et al., 2005; Capitanio et al., 1998). Another study determined that HIV-infected
men who had experienced stressful life events or lacked an adequate support system more
quickly developed AIDS (Glasser et al., 2005; Leserman et al., 1999). Stress has been
found to increase reactivation and enhance lytic viral replication in a number of other
viruses including herpes simplex virus (HSV), Epstein-Barr virus (EBV), and
cytomegalovirus (CMV), so it is possible that stress may have similar effects on the
reactivation of HIV-latently infected cells (Glasser et al., 2005).
It is unclear if stress will affect the establishment of latency and/or viral
reactivation. The viral promoter contains GRE-like sequences, so transcription from the
LTR may be activated by glucocorticoid treatment (Coffin et al., 1997). However, other
transcription factors present at the viral promoter may influence hormone responsiveness
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(Coffin et al., 1997). GR can directly or indirectly alter the activities of NF-kB and AP-1.
Since viral transcription heavily relies on the activity of these host factors, glucocorticoid
exposure may prevent viral reactivation and enhance the establishment of latency. Along
with this, glucocorticoid treatment could induce epigenetic modifications, like
deacetylation of histones near the viral promoter, to augment this latent state. Increased
viral replication has been seen in more clinical models of stress and HIV and in studies
on other viruses as well. Therefore, the possibility that glucocorticoids may enhance viral
reactivation and reduce entrance into latency should not be eliminated.

ALCOHOL AND IMMUNE FUNCTION
Alcohol use is prevalent among HIV-infected individuals, and it is often
associated with increased viral progression to AIDS (Justice et al., 2013; Molina et al.,
2015). Alcohol consumption can have a number of effects in different cell types,
including chromatin remodeling and the generation of reactive oxygen species. These
alcohol-induced changes may potentially effect on the establishment, maintenance and
reactivation of latently infected cells.
Alcohol consumption induces a number of epigenetic modifications including
histone acetylation, methylation and phosphorylation. The metabolism of alcohol leads to
the production of acetate, which gets converted to acetyl CoA, a cofactor for histone
acetyl transferases (HATs) (Samir, 2013). The resulting increase in HAT activity causes
histone acetylation of histone H3 lysine 9 in a variety of tissues (Park et al., 2003; Kim
and Shukla, 2006). DNA methylation can also be affected by alcohol consumption.
Chronic ethanol exposure reduces S-adenosyl methionine (SAM) activity and inhibits
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DNA methyl transferases (DNMTs), causing a global reduction in DNA methylation
(Samir, 2013). In hepatocytes, ethanol treatment causes a reduction in histone H3 lysine 9
methylation and an increase in histone H3 lysine 4 methylation. Alcohol and its
metabolite acetaldehyde have been shown to phosphorylate histone H3 at ser-10 and ser28 (Park et al., 2003) and this phosphorylation is mediated by p38 MAP kinase (Shukla et
al. 2008). All of these epigenetic marks are associated with transcriptional activation,
which causes an increased production of pro-inflammatory cytokines and promotes
exaggerated inflammatory responses (Curtis et al., 2013). This unchecked inflammation
can lead to multi-organ failure and death (Choudry et al., 2008). Recently, one group
demonstrated that while binge drinking causes the down-regulation of various classes of
HDACs, there is actually a binge-ethanol mediated increase in heaptic HDAC3
expression, contributing to liver steatosis and injury in ethanol-treated mice (Kirpich et
al., 2013). Notably, treatment with TSA attenuated HDAC3 expression and liver steatosis
(Kirpich et al., 2013).
Ethanol metabolism also produces reactive oxygen species (ROS) in numerous
cell types. Many cell signaling pathways are regulated by oxidative stress. ROS signaling
activates map kinase pathways leading to AP-1 and NF-kB activation and stimulates the
release of intracellular Ca2+, which results in nuclear translocation of NFAT (Arror et al.,
2004; Thannickal et al., 2000). The effects of ethanol-induced generation of ROS on NFkB activation have been studied in regards to HIV latency. Ethanol treatment resulted in
TNFa-mediated activation of NF-kB and enhanced HIV-1-LTR activity. ROS caused
indirect activation of NF-kB by enhancing the degradation of IkBa, thus allowing NF-kB
nuclear translocation (Dong et al., 2000).
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Enhanced HIV replication due to alcohol treatment has been demonstrated in a
number of studies. Acute alcohol consumption leads to dysregulation of immune function
and increases susceptibility to bacterial and viral infections (Molina et al., 2015). Alcohol
has been shown to significantly increase HIV infection of cord blood monocyte derivedmacrophages by inhibiting the expression of HIV-1 restriction factors such as
APOBEC3G (Mastrogiannis et al., 2014). A study on SIV-infected rhesus macaques
demonstrated increased viral load in alcohol-dependent animals compared to control
groups (Kumar et al., 2005). Other studies have noted significant increases viral
replication in individuals exposed to alcohol prior to HIV infection (Molina et al., 2015).
The specific effects of ethanol on HIV-latently infected CD4+ T cells remains to
be determined. The epigenetic modifications induced by ethanol and the effects of
alcohol exposure in general are multifactorial and tissue specific. Additionally, ethanol
elicits different outcomes depending on the duration of the exposure and amount
consumed (Goral et al., 2008). Increased levels in HIV replication may decrease the
establishment of the latent reservoir, as more viruses are being propagated and more cells
are becoming productively infected. Along with this, emerging data suggests that ethanol
treatment increases transcription from the HIV-LTR and therefore should enhance viral
reactivation (Dong et al., 2000).

SIGNIFICANCE
The existence of latent reservoirs in HIV-infected individuals represents a major
barrier to viral eradication, and current research is focused on eliminating these latently
infected cells. Viral purging with latency reversing agents has seen some success in vitro,
but clinical trials have yielded mixed results. Even though it is clear that multiple
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molecular mechanisms are involved in maintaining the latent state, emerging evidence
suggests that proviral latency is a stochastic event.
Glucocorticoids and ethanol exposure could have profound effects on HIV
latency. Both stimuli alter cell signaling pathways involved in proviral reactivation,
induce chromatin remodeling near the viral promoter, and potentiate or inhibit the
activities of host transcription factors necessary for transcription of the viral genome.
These glucocorticoid and ethanol-induced modifications might explain the apparent
stochasticity attributed to the establishment of latent reservoirs and proviral reactivation.
Given the importance of HIV latency to viral eradication and that stress and alcohol are
often concomitant with HIV infection, the potential impact of these comorbidities on
various aspects of latency warrants further investigation. Insight into the mechanisms of
how stress and alcohol affect the latent reservoir may be important in the development of
effective therapeutics.

CHPATER THREE
METHODS

Cell culture and drug treatments
J-Lat, Jurkat, and CD4+ T cells were cultured in RPMI-1640 medium (Cellgro)
supplemented with 10% fetal bovine serum (FBS), 1,000 U/ml penicillin, 1,000 U/ml
streptomycin and 10 ug/ml ciprofloxacin hydrochloride. 100 U/ml of recombinant human
IL-2 (R&D systems) was added to primary cell cultures. Dexamethasone (SigmaAldrich) was used at final concentrations ranging from 10-5 M to 10-1 0M and ethanol was
used at final concentrations ranging from 17 mM to 65 mM.

Isolation and activation of CD4+ T cells
CD4+ T cells were isolated from peripheral blood mononuclear cells obtained
from unidentified donors. Briefly, PBMCs were isolated from whole blood by density
gradient separation using Lymphocyte Separation Medium (Corning). CD4+ T cells were
separated from PBMCs by negative isolation using a CD4+ T cell isolation kit and LD or
autoMACS columns (Miltenyi). CD4+ T cells were resuspended in RPMI-1640 with IL-2
and placed in 24 well plates pre-coated with 2.5 ug/ml of anti-CD3 (OKT3, eBiosciences)
and 2.5 ug/ml anti-CD28 (CD28.2, BD Biosciences). Cells were stimulated for 3 days.
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Virus production and infection
293T cells were seeded at 60% confluence and transfected with pCMV-VSVg and
R7dEnvGFP using polyethylenimine (PEI). 48h later, the supernatant containing virus
particles was harvested, filtered through a 0.45-um filter (Milipore) and added to cells
with or without 8ug/ml dextran. Cells were infected by 2hr spinoculation at 1200rpm,
13°C, followed by 1hr incubation at 37°C. After incubation, cells were spun down,
resuspended in media with or without dex and ethanol.

Reactivation assays
J-Lat cells were reactivated by 24h treatment with 1 uM of TSA (Sigma-Aldrich),
10 ng/ml TNFα (Peprotech), or 10 nM TPA (Cell Signaling Technologies). Primary
CD4+ T cells were reactivated by placing cells on pre-coated anti-CD3 and anti-CD28
wells in a 96 well U-bottom plate for 48 hours. Cells were cultured in the continued
presence of IL-2.

Flow cytometry / FACS analysis
To measure infectivity, 105 - 106 cells were isolated 48-72h after infection, fixed
in 1% formaldehyde, and analyzed using a BD FACSCanto II flow cytometer. Live cell
populations were defined by forward scatter versus side scatter plots and percent
infectivity was measured by GFP expression. To determine the activation status of CD4+
T cells before and after 3 days of stimulation on anti-CD3 and anti-CD28 antibodies, 105
cells were stained with anti-human CD69-PE (eBioscience) and resuspended in PBS. All
analyses were performed using FlowJo software. For FACS analysis, cells were
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resuspended in PBS and GFP-positive cells were sorted using a FACSAria Sorter.
Collected cells were spun down and resuspended in media with 40% FBS.

Quantitative real-time PCR
For real-time PCR studies, samples from dex, ethanol, or untreated cells were
collected at various time points throughout the experiment. Cells were treated with
RNase A and genomic DNA was extracted according to the DNeasy Blood & Tissue Kit
protocol (Qiagen) and the concentration was determined using a NanoDrop 1000
instrument (Thermo Scientific). 200ng of genomic DNA from each sample was digested
with DpnI (New England BioLabs) for 4-5 hours. Real-time PCR was performed using
previously published primers for proviral DNA and B-actin (Butler et al., 2001, Wu et al.,
2006). Primers for GFP were also used.

CHAPTER FOUR
REACTIVATION OF LATENTLY INFECTED CELLS

INTRODUCTION
One current method for eliminating the latent reservoir is this “shock and kill”
approach, where the virus is purged out of latency by drugs that reactivate latently
infected cells. If this method is going to be used therapeutically, potential inhibitors of
viral reactivation need to be considered. As stress and alcohol are common among HIV
infected patients, it will be important to determine if these two stimuli affect the
reactivation of latently infected cells.
The specific effects of these stimuli are complex and depend on a number of
factors, such as treatment dose and duration. Many studies suggest that chronic and acute
glucocorticoid treatments and alcohol exposure may elicit different effects. It is possible
that different concentrations of dexamethasone and ethanol may have varying effects on
proviral reactivation. We hypothesized that viral reactivation by latency reversing agents
would be altered by ethanol and dexamethasone treatments.
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EXPERIMENTAL DESIGN
J-Lat cell model
To test our hypothesis, we used the J-Lat cell model. These cells harbor
transcriptionally silent HIV provirus that encodes GFP in place of nef. J-Lat cells were
treated with dexamethasone or ethanol for at least 24 hours, then reactivated using a
number of previously tested latency reversing agents (Fig. 1, Table 1). Reactivation was
determined by flow cytometric analysis of GFP expression. Flow data were analyzed
using FlowJo software.

Primary cell model
CD4+ T cells were isolated from PBMCs using lymphocyte separation media,
activated with plate-bound anti-CD3 (2.5 ug/mL) and anti-CD28 (2.5 ug/mL) for 3 days,
then infected by spinoculation with a VSVg pseudotyped HIV-1 reporter virus. 1 hour
after spinoculation, cells were spun down and resuspended in new media +/- dex (10-6 M)
or ethanol (17 mM). 72 hours post-infection, an aliquot of cells from each treatment
group (NT, dex, ethanol) were fixed and GFP expression was analyzed by flow
cytometry. 7 days after infection, cells were reactivated with anti-CD3 (2.5 ug/mL) and
anti-CD28 (2.5 ug/mL). As a negative control, parallel cultures were plated in the
absence of anti-CD3 and anti-CD28. 48h later, GFP expression and proviral DNA content
were analyzed for each treatment group.
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Drug

Mechanism of action

Concentration

Dexamethasone

Synthetic
glucocorticoid

10-5 M – 10-10 M

Ethanol

17 mM – 65 mM

TSA

HDAC inhibitor

1 uM

TNFα

NF-κB activator

10 ng/ml

TPA

PKC activator

10 nM

Table 1. Drugs used for reactivation experiments.

24

Figure 1. Schematic of J-Lat experimental design

Figure 2. Schematic of primary cell experimental design
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RESULTS
To determine how stress and alcohol affect viral reactivation, we used the J-Lat
model. This is an in vitro cell model system to study mechanisms of HIV latency and the
reactivation of latent proviruses. These cells were established by infecting Jurkat T cells
with a GFP reporter virus and sorting all the GFP-negative cells, which essentially
contain uninfected and latently infected populations (Kauder et al., 2009; Spina et al.,
2013). Cells were then treated with TNFa and the GFP-positive cells were sorted and
cloned (Kauder et al., 2009). Under basal conditions, J-Lats express little or no GFP, so
the only way to determine what effects dexamethasone and ethanol treatments have on
these cells is by reactivating them. J-Lat cells reactivate in response to various stimuli
(Fig. 3). Preliminary results suggested that both dexamethasone and ethanol treatments
result in slight decreases in J-Lat reactivation, particularly with TSA and TPA (Fig. 4).
We next examined if this inhibition by ethanol was dose dependent.
Physiologically relevant ethanol concentrations were tested. With increasing ethanol
concentrations, there was a slight dose dependent decrease in J-Lat reactivation by TPA
(Fig. 5). This result was consistent across multiple experiments (data not shown). A very
subtle decrease in J-Lat reactivation was also seen with TSA. However reactivation with
TNFa never yielded a dose dependent decrease. Typically, the number of cells reactivated
with TNFa was consistent across all ethanol concentrations tested but sometimes a slight
increase in reactivation was seen.
To determine if these results changed over time, we cultured J-Lats with low and
high concentrations of dex and ethanol for two weeks. Every day, cells were
supplemented with media +/- dex or ethanol and then reactivated with TSA, TNFa, or
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TPA. Dex and ethanol treatments consistently inhibited reactivation by TPA, while
reactivation with TSA and TNFa closely mimicked the control (Fig. 6).
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Figure 3. J-Lat reactivation by latency reversing agents. J-Lat cells were left untreated
or were treated with TSA (1uM), TNFa (10ng/mL), TPA (10nM) and combinations of
these drugs for 24 hours. GFP expression was analyzed by flow cytometry to determine
the percent of cells reactivated by the indicated drug(s).
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Figure 4. J-Lat reactivation in response to dexamethasone and ethanol exposure. JLat cells were pre-treated with acute dexamethasone (10-5M or 10-6M, 24h) acute ethanol
(170mM, 24h), chronic dexamethasone (10-10M, 4 days) or chronic ethanol (170mM, 4
days). Following dex / EtOH treatments, cells were reactivated with TSA, TNFa, TPA or
combinations of these drugs. Each graph depicts flow cytometry results from reactivation
by a particular drug or combinations of drugs. The percent of cells reactivated (y-axis) in
response to different dex / EtOH treatments (x-axis, light grey bars) was compared to the
no-treatment control (x-axis, dark grey bar).
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Figure 5. J-Lat reactivation in response to increasing ethanol concentrations. J-Lats
were treated with ethanol (0.0173 M, 0.0217 M, 0.0434 M, 0.0686 M, 0.13 M) for 24
hours (acute treatment) or 4 days (chronic treatment). Following ethanol treatments, cells
were given an additional dose of ethanol, then reactivated with TSA, TNFa, or TPA in
triplicates. Proviral reactivation was measured by flow cytometry. Data are represented as
mean +/- SEM.
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Figure 6. Long-term dex and ethanol exposure reveals modest decreases in J-Lat
reactivation by TPA. J-Lats were treated with acute dex (10-5 M), chronic dex (10-10 M)
and ethanol (0.01736 M and 0.065 M) every 24 hours for 2 weeks. Aliquots of cells were
reactivated with TSA, TNFa, and TPA every 1-3 days, and GFP expression was
analyzed. Graphs depict viral reactivation (y-axis) by a specific LRA, in response to dex /
EtOH exposure at the indicated time points (x-axis).
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We next repeated these experiments using a primary cell model. In short, purified
CD4+ T cells were isolated from PBMCs and stimulated with α-CD3/CD28, mimicking
T cell activation in vivo. Activation was measured by CD69 expression. CD69 is a cell
surface marker rapidly upregulated after T cell activation, making it an ideal marker for
determining the activation status of these T cells after three days of stimulation (Fig. 7).
Following 3 days of activation, cells were infected and treated with or without dex (10-6
M) or ethanol (17 mM) for 7 days. Aliquots were taken for flow and real-time PCR
analysis at various time points throughout the experiment.
There is a marked reduction in GFP expression in all treatment groups between 3
and 7 days post-infection (Fig. 8). This loss of GFP expression is indicative of proviruses
becoming latent. If these viruses are latent, there should be potent reactivation in
response to anti-CD3 and anti-CD28 stimulation. However we did not see a change in
GFP expression in reactivated cells compared to unactivated cells (Fig. 9).
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Figure 7. Isolation and activation of CD4+ T cells. Representative dot plots and
histograms of PBMCs prior to CD4+ T cell isolation (top left) and after isolation of CD4+
T cells (top middle). CD4+ T cell activation was measured by CD69 expression (right).
Merged histograms show increased CD69 expression prior to and after T cell activation
(bottom).
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Figure 8. CD4+ T cells lose their GFP expression 1 week post-infection. 1hr after
infection, cells were resuspended in new media with or without dex (10-6 M) or EtOH (17
mM). Aliquots of cells from each treatment group were fixed 3 and 7 days after infection
and GFP expression was determined. Dot plots and histograms show the percent of GFPpositive cells in each treatment group at the indicated time points after infection.
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Unactivated

Reactivated

Figure 9. No significant change in GFP expression between reactivated and
unactivated cells, regardless of treatment conditions. Cells were treated with dex (10-6
M), EtOH (17 mM) or left untreated for 7 days. Cells from each treatment group were
either activated with anti-CD3 and anti-CD28 or left uanctivated. Cells were fixed 48
hours later. Dot plots and histograms show the percent of GFP-positive cells in each
treatment group.
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DISCUSSION
The fundamental issue with this J-Lat experiment is that it depends on the
reactivation of latent cells by potent drugs in order to see any kind of effect
dexamethasone or ethanol treatments may be having. This is problematic for two reasons.
First, many of these drugs are toxic to J-Lats, making data analysis difficult since only a
small percentage of cells will survive treatments with dexamethasone or ethanol plus
reactivating drugs. Lowering drug dosage or duration is not a solution, because cells do
not reactivate at lower concentrations or shorter durations. Second, even if
dexamethasone and ethanol are affecting latency as we predict, we may be unable to see
such effects using this experimental design. Our preliminary studies using J-Lats were
mostly inconclusive, so it was important to test our hypothesis using a primary cell
model. Evidence for this is supported by the previous finding that glucocorticoids
suppress the induction of HIV replication in latently infected primary CD4+ T cells (Chun
et al., 1998).
Unfortunately, our results with primary cells were also inconclusive. Infected
cells lost their GFP expression over time but were unable to be reactivated. Since the
premise of this experiment relies on our ability to reactivate these cells, it is impossible to
determine if these drug treatments affect viral reactivation.

CHAPTER FIVE
ESTABLISHMENT OF LATENCY

INTRODUCTION
Alcohol exposure and stress are commonly associated with HIV infected
individuals, and both stimuli are likely to be involved during the early stages of HIV
infection (i.e. alcohol consumption correlated to risky behavior and HIV contraction or
stress associated with testing HIV-positive) (Justice et al., 2013). As discussed above,
latency is established in CD4+ T cells as they become quiescent, forming long-lived
memory T cells. The silencing of viral expression is mediated by a number of
mechanisms including the absence of host transcription factors and epigenetic
modifications. Since stress and alcohol exposure alter transcription factor activity and the
chromatin environment, it is possible that dexamethasone and ethanol affect the
formation of the latent reservoir. We hypothesized that the number of cells driven into
latency would be altered when cells are treated with dexamethasone or ethanol.

EXPERIMENTAL DESIGN
Jurkat cells
Jurkat T cells were infected with VSVg pseudotyped HIV-1 reporter virus and the
GFP positive cells were sorted. Treatments were started 24 hours after FACS and lasted
50 days. Every day, cells were given dex (10-5 M), ethanol (65 mM) or left untreated.
36
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Every 3-4 days, cells were fixed and GFP expression was analyzed by flow cytometry to
monitor the loss of GFP expression over time. At various time points throughout the
experiment, aliquots of cells were taken for real-time PCR experiments. Genomic DNA
was extracted and digested with DpnI. Real-time PCR was performed for each sample
using LateRT, GFP, and B-actin primers.

Primary cell model
CD4+ T cells were isolated from PBMCs using lymphocyte separation media,
activated with plate-bound anti-CD3 (2.5 ug/mL) and anti-CD28 (2.5 ug/mL), and
infected with a VSVg pseudotyped HIV-1 reporter virus. To enhance infectivity, DEAEDextran was added to virus cultures at a finial concentration of 8 ug/mL. 72 hours after
infection, GFP-positive cells were sorted. Sorted cells were cultured together for an
additional 24 hours in serum-rich media with 20 U IL-2. Cells were then divided into
three groups and treated with dex (10-6 M), ethanol (65 mM), or left untreated. 1 week
later, cells were resuspended in PBS and GFP expression was analyzed by flow
cytometry. Genomic DNA was extracted from remaining cells and digested with DpnI.
Real-time PCR was performed for each sample using LateRT, GFP, and B-actin primers.
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Figure 10. Schematic of Jurkat experimental design

Figure 11. Schematic of primary cell experimental design
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RESULTS
Preliminary data suggested that both dexamethasone and ethanol enhance the size
of the latent reservoir. There was a substantial increase in the percent of GFP-negative
cells when cells were treated for 6 weeks with dexamethasone or ethanol compared to
those left untreated (Fig. 12).
It is possible that the decrease in GFP expression is due to the presence of
uninfected cells that are out-competing the GFP-positive, infected cells. If this is the case,
there will be no provirus present in these GFP-negative cells. However, latently infected
cells will still contain integrated provirus. We did real-time PCR to confirm that the loss
of GFP expression in dex and ethanol treated cells was due to proviral silencing. There
was an evident decrease in the proviral copy number in dex and ethanol treated cells
compared to cells left untreated (Fig. 13). The decrease in integrated provirus correlates
with the loss of GFP expression seen in Fig. 12. These data suggest that the latent
reservoir is not increased by dex or ethanol treatments. Real-time PCR was repeated
using primers to genes downstream of the viral promoter to ensure that epigenetic
modifications were not interfering with primer annealing or SYBR green binding. Similar
results were seen (data not shown).
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Figure 12. Infected Jurkat cells lose GFP expression over time. GFP-positive sorted
cells were treated with dex (10-6 M) or ethanol (65 mM) for 6 weeks. Graphs depict the
changes in GFP expression in cells treated with dex / EtOH (black lines) compared to
untreated cells (red lines).
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Figure 13. Loss of proviral DNA in dex and ethanol treated cells. GFP-positive sorted
cells were treated with dex (10-6 M) or ethanol (65 mM). 30, 35, and 40 days after sorting,
pellets were collected from dex, EtOH, and untreated cells. Genomic DNA was extracted
and digested with DpnI. Real-time PCR was performed for each set of samples in
triplicate using primers for proviral DNA and B-Actin. Graph depicts viral copy number
normalized to actin.
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This experiment was repeated using latently infected primary CD4+ T cells.
Briefly, CD4+ T cells were isolated from PBMCs and activated with anti-CD3 and antiCD28. Once activated, cells were infected and GFP expression was analyzed 48h after
infection (Fig. 14). GFP-positive and negative cells were sorted 72h post-infection. 24
hours after sorting, cells were treated with dex and ethanol. 1 week later, cells were
analyzed for GFP expression and the amount of viral DNA present by flow cytometry
and real-time PCR, respectively (Fig. 15-16). There was a modest reduction in GFP
expression in the untreated group and an even more prominent reduction in the dextreated group, as seen with the Jurkats. Ethanol-treated cells died during the experiment.
Real-time PCR data revealed differences in the amount of proviral DNA present in dex
vs. untreated samples. Surprisingly, there was more viral DNA in the dex-treated cells
compared to the untreated group. As expected, there was no viral DNA in the GFPnegative sorted cells.
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Figure 14. Primary cells infected with VSVg pseudotyped HIV-1 reporter virus.
48h after infection, cells were fixed in 1% formaldehyde and GFP expression was
measured by flow cytometry. 16.1% cells were productively infected, as indicated by
GFP expression.
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Figure 15. GFP expression in GFP-positive sorted cells one week after FACS. GFPpositive sorted cells were treated with dex (10-6 M), ethanol (65 mM), or left untreated for
1 week. Cells were resuspended in PBS and GFP expression was analyzed by flow
cytometry. Dot plots and histograms show the percent of GFP-positive cells within the
live cell population.
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Figure 16. Increased proviral DNA in dex-treated cells compared to the untreated
group. GFP-positive and negative sorted cells were treated with dex (10-6 M), ethanol (65
mM), or left untreated for 1 week. Genomic DNA was extracted and digested with DpnI.
Real-time PCR was performed for each samples using GFP and B-actin primers. Graph
depicts proviral copy number normalized to actin.
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DISCUSSION
Real-time data from Jurkat experiments revealed that the loss of GFP expression
seen in our flow data was not due to these viruses become latent, rather an increased
population of GFP-positive cells in our cell culture. This is a surprising result, as all cells
(NT, dex, and EtOH) came from the same population of productively infected, GFPpositive cells. It is possible that some GFP-negative cells were mistakenly sorted into this
GFP-positive cell population, and these drug treatments provided some kind of selective
advantage to the uninfected cells. It is also probable that dex and ethanol treatments are
enhancing the death of the infected cell population.
In the primary cells, we saw similar flow data where dex-treated cells lose their
GFP expression more quickly than untreated cells. However, real-time PCR data revealed
increased proviral DNA content in cells treated with dexamethasone. The proviral copy
number in this RT-PCR data is abnormally low, particularly in the untreated cells,
suggesting a problem with this data set. We were unable to determine the effects of
ethanol, as these cells died during the experiment.

CHAPTER SIX
CONCLUSIONS AND FUTURE DIRECTIONS

In these studies, we attempted to determine the effects of stress and alcohol on
HIV latency by examining how latency gets established and reactivated in the presence of
glucocorticoids and ethanol. Our initial experiments with J-Lat cells showed modest
reductions in viral reactivation in response to dexamethasone and ethanol exposure. We
saw reproducible inhibition in viral reactivation with TPA after acute and chronic
dexamethasone and ethanol treatments. Other drugs tested did not seem to have this
effect. We were able to successfully establish a latent state in primary CD4+ T cells as
indicated by a pronounced reduction in GFP expression 1 week after infection. However,
data from these experiments were inconclusive since the cells were not reactivated,
despite stimulation with αCD3 and αCD28.
We used a Jurkat cell model to examine how latency gets established in the
context of dexamethasone and ethanol. These cells appeared to become latent within 50
days after infection, and it seemed that both dexamethasone and ethanol were enhancing
the establishment of this latent state. Real-time PCR revealed a reduction in proviral copy
number in these treated cells, compared to the no treatment control. Together, these data
indicate that latency was not established in these cells, rather there was a loss of infected
cells and/or an increase in uninfected cells in the dexamethasone and ethanol treated
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cultures. We developed a model for examining this in primary cells, but a lot of cells
were lost during the infection and sorting processes. We did see a slight reduction in GFP
expression within a week after FACS, and the reduction in GFP expression was more
pronounced in the dexamethasone-treated cells. Real-time data revealed increased viral
DNA content in the dexamethasone-treated cells compared to the no treatment group.
However, due to the very low proviral copy number in these cell populations, we are not
sure if this result is real.
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